Nafamostat for dialysis patients who can't use heparin
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new medicine called nafamostat to prevent blood clots during continuous dialysis (CRRT), for people who are at high risk of bleeding or can't take heparin.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You need to be on continuous dialysis (CRRT), or start it within the last 48 hours
- You cannot use standard blood thinner (heparin) or are at high risk for bleeding
- You must weigh at least 110 pounds (50 kg)
- You cannot currently be on any other blood-thinning medicine
- You cannot have active bleeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two different blood-thinning methods used during continuous kidney-support treatment (CRRT) for patients who have developed severe kidney injury due to sepsis. The goal is to see which method works better and is safer for patients in this critical condition.
This study tests how safe a specific blood thinner called “citrate” is when used during continuous kidney dialysis (CRRT) for people with AKI or kidney failure. If you qualify, your care team will compare citrate safety against standard approaches to see if it’s tolerable and safe.
This trial tests whether finerenone (a medicine that helps protect the kidneys) can improve recovery from acute kidney injury (sudden kidney failure) in hospitalized patients. Participation involves taking the study drug or a placebo while in the hospital.
This study tests whether a medicine called cilastatin can prevent kidney damage caused by certain strong medications. If you are receiving one of these medications and are at risk for kidney injury, this trial may offer protection.
This trial is testing different doses of a blood thinner called nafamostat in patients who are in the ICU and need continuous kidney dialysis (CRRT). The goal is to find which dose works best to prevent clots in the dialysis machine without causing bleeding problems.
This pilot study tests whether nafamostat is safe for people on hemodialysis who have a high risk of bleeding. It may help clinicians find safer ways to manage blood clotting medicines during dialysis.
Hear when a new Acute Kidney Injury trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.